5-[(4-cyclohexylanilino)methyl]-3-(4-methylphenyl)-1-phenyl-7H-pyrazolo[5,4-b]pyridin-6-one
C32H32N4O — CID 135418028
Data last refreshed: (MolForge compound catalog, from PubChem)
About 5-[(4-cyclohexylanilino)methyl]-3-(4-methylphenyl)-1-phenyl-7H-pyrazolo[5,4-b]pyridin-6-one
5-[(4-cyclohexylanilino)methyl]-3-(4-methylphenyl)-1-phenyl-7H-pyrazolo[5,4-b]pyridin-6-one (PubChem CID 135418028) has the molecular formula C32H32N4O and a molecular weight of 488.64 g/mol. Its IUPAC name is 5-[(4-cyclohexylanilino)methyl]-3-(4-methylphenyl)-1-phenyl-7H-pyrazolo[5,4-b]pyridin-6-one.
Molecular Properties
| Compound Name | 5-[(4-cyclohexylanilino)methyl]-3-(4-methylphenyl)-1-phenyl-7H-pyrazolo[5,4-b]pyridin-6-one |
|---|---|
| PubChem CID | 135418028 |
| Molecular Formula | C32H32N4O |
| Molecular Weight | 488.64 g/mol |
| Exact Mass | 488.26 |
| IUPAC Name | 5-[(4-cyclohexylanilino)methyl]-3-(4-methylphenyl)-1-phenyl-7H-pyrazolo[5,4-b]pyridin-6-one |
| SMILES | Cc1ccc(-c2nn(-c3ccccc3)c3[nH]c(=O)c(CNc4ccc(C5CCCCC5)cc4)cc23)cc1 |
| InChI | InChI=1S/C32H32N4O/c1-22-12-14-25(15-13-22)30-29-20-26(32(37)34-31(29)36(35-30)28-10-6-3-7-11-28)21-33-27-18-16-24(17-19-27)23-8-4-2-5-9-23/h3,6-7,10-20,23,33H,2,4-5,8-9,21H2,1H3,(H,34,37) |
| InChIKey | ILXUZSPJJSPISQ-UHFFFAOYSA-N |
| XLogP | 7.35 |
| TPSA | 62.71 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 4 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 37 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 488.64 |
| LogP ≤ 5 | 7.35 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 4 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 135418028 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.